290 related articles for article (PubMed ID: 25289928)
21. Osteocytes produce interferon-β as a negative regulator of osteoclastogenesis.
Hayashida C; Ito J; Nakayachi M; Okayasu M; Ohyama Y; Hakeda Y; Sato T
J Biol Chem; 2014 Apr; 289(16):11545-11555. PubMed ID: 24610813
[TBL] [Abstract][Full Text] [Related]
22. Effect of TNF-
Ohori F; Kitaura H; Marahleh A; Kishikawa A; Ogawa S; Qi J; Shen WR; Noguchi T; Nara Y; Mizoguchi I
J Immunol Res; 2019; 2019():9716758. PubMed ID: 31341915
[TBL] [Abstract][Full Text] [Related]
23. Fluid Shear Stress Increases Osteocyte and Inhibits Osteoclasts via Downregulating Receptor-Activator of Nuclear Factor κB (RANK)/Osteoprotegerin Expression in Myeloma Microenvironment.
Wang X; He Y; Tian S; Zhu F; Huang B; Zhang J; Chen Z; Wang H
Med Sci Monit; 2019 Aug; 25():5961-5968. PubMed ID: 31400110
[TBL] [Abstract][Full Text] [Related]
24. The role of osteocytes in targeted bone remodeling: a mathematical model.
Graham JM; Ayati BP; Holstein SA; Martin JA
PLoS One; 2013; 8(5):e63884. PubMed ID: 23717504
[TBL] [Abstract][Full Text] [Related]
25. Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
McDonald MM; Reagan MR; Youlten SE; Mohanty ST; Seckinger A; Terry RL; Pettitt JA; Simic MK; Cheng TL; Morse A; Le LMT; Abi-Hanna D; Kramer I; Falank C; Fairfield H; Ghobrial IM; Baldock PA; Little DG; Kneissel M; Vanderkerken K; Bassett JHD; Williams GR; Oyajobi BO; Hose D; Phan TG; Croucher PI
Blood; 2017 Jun; 129(26):3452-3464. PubMed ID: 28515094
[TBL] [Abstract][Full Text] [Related]
26. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
28. Evidence for osteocyte regulation of bone homeostasis through RANKL expression.
Nakashima T; Hayashi M; Fukunaga T; Kurata K; Oh-Hora M; Feng JQ; Bonewald LF; Kodama T; Wutz A; Wagner EF; Penninger JM; Takayanagi H
Nat Med; 2011 Sep; 17(10):1231-4. PubMed ID: 21909105
[TBL] [Abstract][Full Text] [Related]
29. Regulatory mechanisms of RANKL presentation to osteoclast precursors.
Honma M; Ikebuchi Y; Kariya Y; Suzuki H
Curr Osteoporos Rep; 2014 Mar; 12(1):115-20. PubMed ID: 24477414
[TBL] [Abstract][Full Text] [Related]
30. The osteocyte and its osteoclastogenic potential.
Marahleh A; Kitaura H; Ohori F; Noguchi T; Mizoguchi I
Front Endocrinol (Lausanne); 2023; 14():1121727. PubMed ID: 37293482
[TBL] [Abstract][Full Text] [Related]
31. The Osteocyte as a Novel Key Player in Understanding Periodontitis Through its Expression of RANKL and Sclerostin: a Review.
de Vries TJ; Huesa C
Curr Osteoporos Rep; 2019 Jun; 17(3):116-121. PubMed ID: 30924022
[TBL] [Abstract][Full Text] [Related]
32. IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity In Vitro.
Wu Q; Zhou X; Huang D; Ji Y; Kang F
Cell Physiol Biochem; 2017; 41(4):1360-1369. PubMed ID: 28278513
[TBL] [Abstract][Full Text] [Related]
33. IL-6 exhibits both
McGregor NE; Murat M; Elango J; Poulton IJ; Walker EC; Crimeen-Irwin B; Ho PWM; Gooi JH; Martin TJ; Sims NA
J Biol Chem; 2019 May; 294(19):7850-7863. PubMed ID: 30923130
[TBL] [Abstract][Full Text] [Related]
34. Parathyroid hormone (PTH)/PTH-related peptide type 1 receptor (PPR) signaling in osteocytes regulates anabolic and catabolic skeletal responses to PTH.
Saini V; Marengi DA; Barry KJ; Fulzele KS; Heiden E; Liu X; Dedic C; Maeda A; Lotinun S; Baron R; Pajevic PD
J Biol Chem; 2013 Jul; 288(28):20122-34. PubMed ID: 23729679
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
[TBL] [Abstract][Full Text] [Related]
36. The osteocyte plays multiple roles in bone remodeling and mineral homeostasis.
Chen H; Senda T; Kubo KY
Med Mol Morphol; 2015 Jun; 48(2):61-8. PubMed ID: 25791218
[TBL] [Abstract][Full Text] [Related]
37. Avenanthramides Prevent Osteoblast and Osteocyte Apoptosis and Induce Osteoclast Apoptosis in Vitro in an Nrf2-Independent Manner.
Pellegrini GG; Morales CC; Wallace TC; Plotkin LI; Bellido T
Nutrients; 2016 Jul; 8(7):. PubMed ID: 27409635
[TBL] [Abstract][Full Text] [Related]
38. [Bone tissue and cancer].
Rossi JF
Pathol Biol (Paris); 1990 Jan; 38(1):69-79. PubMed ID: 2407992
[TBL] [Abstract][Full Text] [Related]
39. The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.
Spatz JM; Wein MN; Gooi JH; Qu Y; Garr JL; Liu S; Barry KJ; Uda Y; Lai F; Dedic C; Balcells-Camps M; Kronenberg HM; Babij P; Pajevic PD
J Biol Chem; 2015 Jul; 290(27):16744-58. PubMed ID: 25953900
[TBL] [Abstract][Full Text] [Related]
40. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
